In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2007

Executive Summary

In this issue, we present another installment of our quarterly review of pharmaceutical/biotechnology dealmaking-for July-September 2007. Our data come from Windhover's Strategic Transactions Database.

Related Content

Bristol Revs Its R&D Engine: An Interview with Elliott Sigal and Francis Cuss
Big Pharma's Leap into Biologics: Bridging both Scientific and Cultural Gaps
Alnylam, Isis JV Regulus to Tackle MicroRNA
The Eyes Still Have It: Finding Cures For Diseases that Blind Remains Top Focus for Investors, Entrepreneurs
NovaCardia & Domain: New-Model Spec Pharma Investing
Alnylam Takes Platform Monetization to a Whole New and Non-Exclusive Level
Biotech IPOs: Why Values Will Increase
The Large Molecule Future
Novartis Opens Door to Broad Dealmaking in RNAi


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts